Adherence to Subcutaneous Anti-Tumour Necrosis Factor Treatment in a Cohort of Patients with Rheumatoid Arthritis Before and After the Implementation of a Comprehensive Care Model.

Pedro Santos-Moreno Guillermo Sánchez-Vanegas Angelica Monterrosa-Blanco Gabriel-Santiago Rodríguez-VargasManuel RiveroPedro A Rodríguez Omar-Javier Calixto Adriana Rojas-Villarraga Carlos Alberto Castro

Published in: Biologics : targets & therapy (2022)

A CCM produced an important increase in the percentage of patients with rheumatoid arthritis adherent to treatment after 24 months of follow-up. It is noteworthy that Golimumab patients were more adherent when compared with other current anti-TNFs treatments.

Keyphrases

healthcare
end stage renal disease
ejection fraction
palliative care
primary care
quality improvement
peritoneal dialysis
type diabetes
rheumatoid arthritis
prognostic factors
adipose tissue
ankylosing spondylitis
systemic lupus erythematosus
pain management
affordable care act